These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 32967471)

  • 41. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
    Ciciriello S; Littlejohn GO; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT
    Clin Exp Rheumatol; 2024 Sep; 42(9):1763-1772. PubMed ID: 38757292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies.
    Lauper K; Hyrich KL
    Expert Rev Clin Immunol; 2022 Mar; 18(3):207-220. PubMed ID: 34528855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
    Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
    Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Janus Kinase Inhibitors: Next-Generation Treatment for Uveitis.
    El-Shabrawi Y; Rath T; Heiligenhaus A
    Klin Monbl Augenheilkd; 2022 May; 239(5):695-701. PubMed ID: 35426113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update.
    Chuprin J; McCormack L; Richmond JM; Rashighi M
    Expert Rev Clin Immunol; 2022 Mar; 18(3):263-272. PubMed ID: 35209781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.
    Popa CD; Opdam MAA; den Broeder N; van Ballegooijen H; Mulder K; van de Wiel KM; van Herwaarden N; Wientjes MHM; den Broeder AA
    Rheumatology (Oxford); 2024 Aug; 63(8):2142-2146. PubMed ID: 37796830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets.
    Lui SW; Hsieh TY; Lu JW; Chen YC; Lin TC; Ho YJ; Liu FC
    APMIS; 2023 Sep; 131(9):498-509. PubMed ID: 37439387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Filgotinib in rheumatoid arthritis.
    Westhovens R
    Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
    O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
    Front Immunol; 2021; 12():672461. PubMed ID: 34248953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
    Boyce EG; Rogan EL; C Lui M
    Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G; Bertoldi I; Rossini M
    Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
    Adam S; Simon N; Steffen U; Andes FT; Scholtysek C; Müller DIH; Weidner D; Andreev D; Kleyer A; Culemann S; Hahn M; Schett G; Krönke G; Frey S; Hueber AJ
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.